An international, non-interventional, post-authorization long-term safety study of LUTATHERA®, in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (SALUS study).


1Moffitt Cancer Center, Tampa, FL 33612, USA; 2Royal Free Hospital, London, United Kingdom; 3Advanced Accelerator Applications, a Novartis Company, New York, NY, USA; 4Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland; 5Erasmus Medical Center, Rotterdam, Netherlands

After market authorization, FDA / EMA recommended to assess the long-term safety profile of LUTATHERA® according to the label indication (SmPC/USPI)

**Active substance**
- INN: lutetium (177Lu) oxodotreotide
- USAN: lutetium Lu 177-DOTATATE
- ATC code: V10XX04

**Medicinal product**
- LUTATHERA® 370 MBq/mL solution for infusion

**Marketing authorization holder**
- Advanced Accelerator Applications, a Novartis Company
- 4 rue de la tour de l’île
- 1204 Geneva- Switzerland

### METHODS

#### Primary research-objective
- Incidence assessment and nature of potential long term second primary malignancies, including solid tumours and haematological neoplasia, in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive GEP-NET

#### Secondary research-objectives
- Risk Management Plan (RMP) for:
  - renal dysfunction
  - myelosuppression/cytopenias
  - myelodysplastic syndrome
  - hypogonadism
  - sexual dysfunction
  - drug-drug interaction SST
  - tumour cell lysis-related hormone release-induced crises
  - hepatotoxicity, radiotoxicity

- Detection of potential new risks overall, and potential risks in patients under-represented in the clinical trial, including elderly patients, patients with renal and liver impairment, reduced bone-marrow reserve, exposure in breast-feeding women, accidental foetal and child exposure.

- Description of drug patterns utilisation that may add knowledge about the safety of LUTATHERA®

#### Inclusion criteria
- Adult patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive GEP-NET treated with LUTATHERA®, regardless of the quantity and number of doses administered and whatever the reasons for ending

#### Exclusion criteria
- Hypersensitivity to LUTATHERA®
- Presence of established or suspected pregnancy or pregnancy not excluded
- Presence of kidney failure with creatinine clearance < 30 mL/min

#### Follow up of 4 years for prospective study and 4-7 years for retrospective + prospective

All patients will be documented for their second primary tumour and living status during follow-up period from 4 - 7 years, via investigators and/or contact with the patients

#### Sites and cohort size
- ~1000 patients
- US : 8 sites
- Europe : 13 sites
Results

Data analysis

Descriptive statistics will be presented for the overall full analysis set, and by potential risk factors including:
- Continuous variables will be summarized by the number of observations, mean, standard deviation, median, minimum, and maximum.
- Categorical variables will be summarized by frequency counts and percentages for each category.
- Baseline will be the last assessment of the variable under consideration prior to the intake of the first dose of LUTATHERA®.

Planned Milestones

- Q4 2017: PRAC/FDA protocol submission
- Q3-Q4 2018: Start of data collection
- Q3 2020: Last patient treated
- Q4 2025: Final report of study results
- Q3 2018: PRAC/FDA final opinion on protocol
- Registrations: EU PAS register + US clinicaltrials.gov website
- Q4 2024: End of data collection

Final report to be submitted within 12 months of the end of data collection.

Conclusions

The Salus registry shall provide important real world data on long term safety profile and benefits of LUTATHERA®.